Tag:

AbbVie

Latest Headlines

Latest Headlines

AbbVie heads to the FDA with its hep C combo in a race with Gilead, Merck

AbbVie has submitted an FDA application for its promising all-oral hepatitis C treatment, expecting approval this year as it prepares for a three-way race with perceived leaders Gilead Sciences and Merck.

AbbVie careful about gay rights in its discussion of a new trial

AbbVie has asked a federal appeals panel to decide whether a new trial is really warranted in its case with GlaxoSmithKline over the price of an HIV drug. But the drugmaker was very careful to point out that it is not asking the court to disrupt any rights that gays and lesbians have achieved through a recent Supreme Court ruling.

AbbVie angles for hep C spotlight as Merck shoulders to the front

While AbbVie is widely expected to be the second entrant to the soon-to-explode market for hepatitis C cocktail drugs after standard-bearer Gilead Sciences, promising data from latecomer Merck have analysts relegating the Illinois company to third place despite some excellent late-stage results.

AbbVie joins peers in Middle East with Saudi Arabia plans

Its deal for Arab Pharmaceutical Product Company (Arabio) to manufacture Humira and other drugs in the kingdom is seen as a significant advance in the country's ability to manufacture biologics.

Which brands grab the drug-spending title? AbbVie's Humira, AZ's Nexium lead the way

Which drugs cost U.S. health plans the most? Take a look at this year's iteration of Express Scripts' annual Drug Trend Report, and you'll find commentary on drug prices, the pharma industry, and American society. Not to mention a hint at which brands are best at getting themselves noticed.

AbbVie gets out of the way as the EU prepares for trial transparency

Amid a continental push to make more clinical trial results available to the public, the European Medicines Agency has apparently assuaged a former foe in AbbVie, as the drugmaker dropped a lawsuit designed to block the release of data on its blockbuster Humira.

UPDATED: AbbVie CEO's pay doubles to $18.2M in Abbott pharma spinoff's first solo year

AbbVie CEO Richard Gonzalez has been on the job for just over a year, and already his pay has more than doubled. As chief of the newly minted pharma company, spun off from Abbott Laboratories last January 1, Gonzalez racked up $18.2 million in 2013 compensation, including $3.3 million in incentive pay.

AbbVie's hep C cocktail aces its latest PhIII study with a sky-high cure rate

AbbVie's promising oral hepatitis C combo treatment is rolling along toward FDA approval, and the drugmaker unveiled a deeper set of Phase III data in which the cocktail cured nearly 100% of patients in a tough-to-treat population.

AbbVie, Amgen and Roche most vulnerable to biosim rivals, Moody's says

As the biosimilar market takes shape, companies are gunning to produce copies of some of the world's top-selling drugs. And according to a new Moody's report, with their star products wearing targets on their backs, AbbVie, Amgen and Roche are most exposed to the new competition.

Gilead hands its hep C combo to the FDA as AbbVie race heats up

Right on schedule, Gilead Sciences has submitted its combination hepatitis C treatment for FDA approval, inching toward the era of interferon-free treatment and widening its lead on rival AbbVie.